Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

78223

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what information is in place to inform girls of the human papilloma virus vaccine and its risks.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1118
answer	answer is ministerial correction date of answer 29/07/2014 answer text <p>A wide range of information about human papillomavirus (HPV) immunisation is available. This includes leaflets, vaccination record cards, information on the NHS Choices website, and more detailed clinical guidance to health professionals who are able to advise girls on both the benefits and risks of HPV immunisation. The potential side effects of HPV vaccine are also described in the product information (the Summary of Product Characteristics for healthcare professionals and the Patient Information Leaflet which is included in the pack of each dose of vaccine).</p><p> </p><p>HPV immunisation has a very good safety record, and plays a significant role in reducing the risks of girls contracting cervical cancer as they grow older.</p><p> </p><p> </p> answering member printed Earl Howe question first answered 29/07/2014 11:33:53 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78224

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans, if any, they have to introduce the human papilloma virus vaccine for boys.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1119
answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the Government’s expert advisers on immunisation matters, has set up a human papillomavirus (HPV) sub-committee to consider a number of key issues around HPV vaccination, including vaccinating men who have sex with men (MSM) and potential extension of the current programme to include adolescent boys.</p><p> </p><p>The HPV sub-committee will report its findings to the JCVI following consideration of studies by Public Health England on the impact and cost-effectiveness of extending HPV vaccination to MSM or adolescent boys. It is expected that the MSM modelling study will be completed at the end of 2014 at the earliest, and the adolescent boys modelling study will be completed at the end of 2015 at the earliest</p><p><strong> </strong></p><p>The Department will consider carefully the advice from the JCVI once it has completed its assessment.</p> answering member printed Earl Howe question first answered 23/07/2014 12:33:02 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78225

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the care received by girls suffering from vaccine injury related to the human papilloma virus vaccine.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1120
answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The Department has not made such an assessment. The Medicines and Healthcare products Regulatory Agency (MHRA), has closely evaluated the safety of Human papillomavirus (HPV) vaccine since introduction in the national immunisation programme in 2008. In September 2012 the MHRA sought advice from the Commission on Human Medicines (CHM) on the safety of HPV vaccine, which advised that no new safety concerns have been identified and the balance of risks and benefits of the vaccine remains positive.</p><p><strong> </strong></p><p>The MHRA reviews are available on the MHRA website:</p><p> </p><p><a href="http://www.mhra.gov.uk/HPVvaccine" target="_blank">www.mhra.gov.uk/HPVvaccine</a>.</p><p> </p><p>The MHRA continues to closely evaluate the safety of Gardasil HPV vaccine since it replaced Cervarix in 2012.</p> answering member printed Earl Howe question first answered 23/07/2014 12:32:18 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78226

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sickle Cell Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many patients in each parliamentary constituency have sickle cell disease.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1121
answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The vast majority of sickle cell disease (SCD) affected children born in England are identified by the NHS Sickle Cell and Thalassaemia Screening programme, and other patients may present through migration or late diagnosis</p><p> </p><p>SCD is a lifelong condition, and NHS England provides high quality care for patients with SCD as part of its specialised commissioning responsibilities. NHS England’s Haemaglobinopathies service specification clearly sets out what providers must have in place for providers to offer evidence-based, safe and effective services.</p><p> </p><p>Although SCD patient care will be coordinated by a Specialist Haemoglobinopathy Centre (SHC), the majority of care may be delivered outside of the SHC by a range of providers. The configuration of care provision will be based on local prevalence, expertise and availability of service providers, and this may include acute hospitals, community care, primary care and the voluntary sector.</p><p> </p><p>Information concerning the number of SCD patients in each parliamentary constituency is not collected. However, NHS England’s service specification sets out that there are around 15,000 patients with SCD living in England at present. In England SCD occurs predominantly, but not exclusively, in ethnic minority communities. It is the most common inherited condition in England and around 350 babies with SCD are born each year.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1122 HL1123 question first answered 23/07/2014 12:31:24 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78227

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sickle Cell Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what trends they have identified in the prevalence of sickle cell disease in the United Kingdom over the last 10 years.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1122
answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The vast majority of sickle cell disease (SCD) affected children born in England are identified by the NHS Sickle Cell and Thalassaemia Screening programme, and other patients may present through migration or late diagnosis</p><p> </p><p>SCD is a lifelong condition, and NHS England provides high quality care for patients with SCD as part of its specialised commissioning responsibilities. NHS England’s Haemaglobinopathies service specification clearly sets out what providers must have in place for providers to offer evidence-based, safe and effective services.</p><p> </p><p>Although SCD patient care will be coordinated by a Specialist Haemoglobinopathy Centre (SHC), the majority of care may be delivered outside of the SHC by a range of providers. The configuration of care provision will be based on local prevalence, expertise and availability of service providers, and this may include acute hospitals, community care, primary care and the voluntary sector.</p><p> </p><p>Information concerning the number of SCD patients in each parliamentary constituency is not collected. However, NHS England’s service specification sets out that there are around 15,000 patients with SCD living in England at present. In England SCD occurs predominantly, but not exclusively, in ethnic minority communities. It is the most common inherited condition in England and around 350 babies with SCD are born each year.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1121 HL1123 question first answered 23/07/2014 12:31:24 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78228

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sickle Cell Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is their strategy towards the treatment of sickle cell disease.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1123
answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The vast majority of sickle cell disease (SCD) affected children born in England are identified by the NHS Sickle Cell and Thalassaemia Screening programme, and other patients may present through migration or late diagnosis</p><p> </p><p>SCD is a lifelong condition, and NHS England provides high quality care for patients with SCD as part of its specialised commissioning responsibilities. NHS England’s Haemaglobinopathies service specification clearly sets out what providers must have in place for providers to offer evidence-based, safe and effective services.</p><p> </p><p>Although SCD patient care will be coordinated by a Specialist Haemoglobinopathy Centre (SHC), the majority of care may be delivered outside of the SHC by a range of providers. The configuration of care provision will be based on local prevalence, expertise and availability of service providers, and this may include acute hospitals, community care, primary care and the voluntary sector.</p><p> </p><p>Information concerning the number of SCD patients in each parliamentary constituency is not collected. However, NHS England’s service specification sets out that there are around 15,000 patients with SCD living in England at present. In England SCD occurs predominantly, but not exclusively, in ethnic minority communities. It is the most common inherited condition in England and around 350 babies with SCD are born each year.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1121 HL1122 question first answered 23/07/2014 12:31:23 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

77796

registered interest
date	14/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what steps they plan to take to encourage early diagnosis of neurofibromatosis Type 1.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1093
answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>Neurofibromatosis Type 1 (NF1) patients are included within the remit of Dr David Bateman in his role as National Clinical Director for Chronic Disability and Neurological Conditions at NHS England.</p><p> </p><p>There are currently no plans for awareness raising activity in relation to NF 1, which is an inherited condition. Information for the public on the diagnosis and treatment of NF1 can be found on the NHS Choices website, which sets out the key signs and symptoms of the condition, including: coffee colored patches on the skin, two or more neurofibromas (bumps on or under the skin); bone defects, such as bowing of the lower leg; and, a family history of NF1. The NF1 webpages can be viewed at the following link:</p><p> </p><p>www.nhs.uk/conditions/Neurofibromatosis/Pages/Introduction.aspx.</p><p> </p><p>More detailed information for general practitioners and other health professionals can be found on the National Institute for Health and Care Excellence NHS Evidence website:</p><p> </p><p>www.evidence.nhs.uk.</p><p> </p><p>This provides free access to quality health and social care evidence and best practice.</p> answering member printed Earl Howe grouped question UIN HL1094 HL1096 question first answered 22/07/2014 16:22:11 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

77797

registered interest
date	14/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which National Clinical Director has responsibility for overseeing the National Health Service response to neurofibromatosis Type 1.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1094
answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>Neurofibromatosis Type 1 (NF1) patients are included within the remit of Dr David Bateman in his role as National Clinical Director for Chronic Disability and Neurological Conditions at NHS England.</p><p> </p><p>There are currently no plans for awareness raising activity in relation to NF 1, which is an inherited condition. Information for the public on the diagnosis and treatment of NF1 can be found on the NHS Choices website, which sets out the key signs and symptoms of the condition, including: coffee colored patches on the skin, two or more neurofibromas (bumps on or under the skin); bone defects, such as bowing of the lower leg; and, a family history of NF1. The NF1 webpages can be viewed at the following link:</p><p> </p><p>www.nhs.uk/conditions/Neurofibromatosis/Pages/Introduction.aspx.</p><p> </p><p>More detailed information for general practitioners and other health professionals can be found on the National Institute for Health and Care Excellence NHS Evidence website:</p><p> </p><p>www.evidence.nhs.uk.</p><p> </p><p>This provides free access to quality health and social care evidence and best practice.</p> answering member printed Earl Howe grouped question UIN HL1093 HL1096 question first answered 22/07/2014 16:22:12 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

77799

registered interest
date	14/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans they have to increase awareness amongst midwives and general practitioners of neurofibromatosis Type 1.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1096
answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>Neurofibromatosis Type 1 (NF1) patients are included within the remit of Dr David Bateman in his role as National Clinical Director for Chronic Disability and Neurological Conditions at NHS England.</p><p> </p><p>There are currently no plans for awareness raising activity in relation to NF 1, which is an inherited condition. Information for the public on the diagnosis and treatment of NF1 can be found on the NHS Choices website, which sets out the key signs and symptoms of the condition, including: coffee colored patches on the skin, two or more neurofibromas (bumps on or under the skin); bone defects, such as bowing of the lower leg; and, a family history of NF1. The NF1 webpages can be viewed at the following link:</p><p> </p><p>www.nhs.uk/conditions/Neurofibromatosis/Pages/Introduction.aspx.</p><p> </p><p>More detailed information for general practitioners and other health professionals can be found on the National Institute for Health and Care Excellence NHS Evidence website:</p><p> </p><p>www.evidence.nhs.uk.</p><p> </p><p>This provides free access to quality health and social care evidence and best practice.</p> answering member printed Earl Howe grouped question UIN HL1093 HL1094 question first answered 22/07/2014 16:22:10 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

77800

registered interest
date	14/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what progress the sub-committee on human papilloma virus vaccines of the Joint Committee on Vaccination and Immunisation has made.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1097
answer	answer is ministerial correction date of answer 28/07/2014 answer text <p>The Human papilloma virus (HPV) sub-committee met for the first time on 20 January 2014 to review available evidence on the impact and cost-effectiveness of potential extensions to the HPV vaccination programme including vaccinating men who have sex with men (MSM) and/or adolescent boys.</p><p> </p><p>The HPV sub-committee will report its findings to the Joint Committee on Vaccination and Immunisation (JCVI) following consideration of on-going studies by Public Health England on the impact and cost-effectiveness of extending HPV vaccination to MSM or adolescent boys. The subcommittee requested that on-going work by Public Health England to model the impact cost effectiveness of targeted MSM vaccination report as early as possible, and advised that an individual based model should be developed to look at the impact and cost effectiveness of universal vaccination of adolescent boys.</p><p> </p><p>In January 2014 the HPV Subcommittee also advised moving from a three dose vaccination schedule to a two dose schedule for adolescent females and this was endorsed by JCVI in February 2014 and will be implemented in September 2014.</p><p> </p><p>The HPV Subcommittee will next be meeting in autumn 2014 to consider the latest evidence for the potential extensions to the HPV vaccination programme.</p><p> </p> answering member printed Earl Howe question first answered 28/07/2014 16:34:18 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath